Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

NCT04305236 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Halted due to study funding

Conditions

Breast Neoplasm
Hormone Receptor Positive Breast Carcinoma

Interventions

DRUG: Abemaciclib
DRUG: Fulvestrant

Sponsor

University of California, Irvine

Collaborators

[object Object]